Cardiología Efecto de dos inhibidores de la fosfodiesterasa 5, sildenafil y vardenafil sobre la arteria pulmonar principal de la rata sometida a condiciones de hipoxia
Ghofrani, B. Tsai, H. Wang, Mark W. Turrentine, Y. Mahomed, John W. Brown, y col, Hypoxic pulmonary vasoconstrictionincardiothoracicsurgery:basicmechanismstopotentialtherapies.AnnThoracSurg.78:360-368.2004
Pauvert O, Savail D, Rousseau E, Lugnier C, Marthan R, and Savineau J. Characterization of cyclic nucleotide phosphodiesteraseisoformsinthemedialayerofthemainpulmonaryartery. Biochem Pharmacol63:1763-1772,2002
RabeK,Tenor H, DentG,Schudt C, NakashimaM,and Magnussen H. 1dentificationofPDE isoenzymes inhumanpulmonaryarteryandeffectofselectivePDEinhibitors.AmJPhysiolLungCellMolPhysiol266:L536-L543,1994
Michelakis E, Tymchak W, Noga M, Webster L, Wu XC, y col, Long-term treatment with oral sildenafil is safe and improvesfunctionalcapacityandhemodynamicsinpatientswithpulmonaryarterialhypertension.Circulation108:2066-2069, 2003.
Murray F,MacLeanM,andPyne N. 1ncreased expressiononthecGMP-inhibitedcAMP-specific(PDE3)andcGMPbindingcGMP-specific(PDE5)phosphodiesterasesinmodelsof pulmonaryhypertension.BrJPharmacol137:1187-1194, 2002.
ChinoseF, Erana-Garcia J, Hromi J, Raveh Y, Jones R, KrimL, y col,Nebulizedsildenafilis a selective pulmonaryvasodilatorinlambswithacutepulmonaryhypertension.CritCareMed29:1000-1005,2001
Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, and Archer S. Oral sildenafil is an effective and specific pulmonaryvasodilatorinpatientswithpulmonaryarterialhypertension.Comparisonwithinhalednitricoxide.Circulation105: 2398-2403,2002.
Lalande S, Snyder E, Olson T, Hulsebus M, Orban M, Somers V, Johnson B and Frantz R.The effects of sildenafil and acetazolamideonbreathing efficiencyandventilatorycontrolduringhypoxicexercise.EurJApplPhysiol.106(4):509-515.2009
Ghofrani, H; Voswinckel, R; Reichenberger, F; Olschewski, H; Haredza, P y col. Differences in hemodynamic and oxygenationresponsetothreedifferentphosphodiesterase-5inhibitorsinpatientswithpulmonaryarterialhypertension.J. Am.CollCardiol.2004.44(7):1488-1496
Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH and Corbin JD (2004) Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66:144-152.
Teixeira, C.Priviero, F. andR.Webb, C. DifferentialEffectsofthePhosphodiesteraseType5 1nhibitorsSildenafil,Vardenafil,andTadalafilinRatAorta.JPET316:654-661,2006
NagaokaT,MorioY, Casanova N, Bauer N, Gebb S, McMurtry 1,andOkaM.Rho/Rho-kinasesignalingmediatesincreasedbasalpulmonaryvasculartoneinchronicallyhypoxicrats.AmJPhysiol.287:L665-L672.2004
Mochida H, 1noueH, Takagi M,NotoT,YanoK,andKikkawa K . Sildenafiland T-1032, phosphodiesterase type 5 inhibitors,showedadifferentvasorelaxantpropertyintheisolatedrataorta.EurJPharmacol440:45-52.2002
Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, and Archer S. Oral sildenafil is an effective and specific pulmonaryvasodilatorinpatientswithpulmonaryarterialhypertension.Comparisonwithinhalednitricoxide.Circulation105: 2398-2403,2002.
Pauvert O, Lugnier C, Keravis T, Marthan R, Rousseau E, and Savineau JP. Effect of sildenafil on cyclic nucleotide phosphodiesteraseactivity,vasculartoneandcalciumsignalinginratpulmonaryartery.BrJPharmacol139:513-522,2003
GhofraniH,WiedemannR,RoseF,Schermuly RT,OlschewskiH,WeissmannN,Gunther A,WalmrathD,Seeger W, Grimminger F.Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.Lancet. 2002;360(9337):895-900
Michelakis E, Tymchak W, Noga M, Webster L, Wu XC, y col, Long-term treatment with oral sildenafil is safe and improvesfunctionalcapacityandhemodynamicsinpatientswithpulmonaryarterialhypertension.Circulation108:2066-2069, 2003.
Ghofrani, H; Voswinckel, R; Reichenberger, F; Olschewski, H; Haredza, P y col. Differences in hemodynamic and oxygenationresponsetothreedifferentphosphodiesterase-5inhibitorsinpatientswithpulmonaryarterialhypertension.J. Am.CollCardiol.2004.44(7):1488-1496
Risau W. Mechanisms of angiogenesis. Nature. 1997;386: 671– 674.
Makoto, S., Sata, M., Toshihiro, M., Toshiaki, N, , Yasunobu, H. and Ryozo, N. A Phosphodiesterase-5 Inhibitor Vardenafil Enhances Angiogenesis Through a Protein Kinase G–Dependent Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway. Arterioscler Thromb Vasc Biol 2010, 30:1315-1324.
Schlossmann, J. and Schinner, E. cGMP becomes a drug target. Naunyn-Schmiedeberg's Arch Pharmacol. 385: 243–252. 2012
Cohen AH, Hanson K, Morris K, et al. Inhibition of cyclic 3’-5’-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 1996;97:172–9.
Tsai, B; Mark W; Turrentine, M, Sheridan y col. ,Differential Effects of Phosphodiesterase-5 Inhibitors on Hypoxic Pulmonary Vasoconstriction and Pulmonary Artery Cytokine Expression. Ann Thorac Surg 2006;81:272– 8
Golombek, S; Sola, A; Lemus, L. y col. Recomendaciones del VI Consenso Clínico de SIBEN para la Hipertensión Pulmonar Persistente del Recién Nacido. NeoReviews. 2017; 18: e327-3440
NOTA:Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.
Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO, caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit